Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Indaptus Therapeutics, Inc.INDP · Entity 6530 | Director | June 10, 2025 | June 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Indaptus Therapeutics, Inc.
Report date June 10, 2025 · Filed June 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.33 · Expires 2035-06-10 | Direct | 12,500 |
Reported balance
After 2025-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-10 · Grant · Acquired 12,500 · Balance 12,500 F1: The stock option vests and becomes exercisable on June 10, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable on June 10, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2025 Filed Jun 11, 2025 20:05 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001641172-25-014690 · ownership.xml · derivative · entry 1 Gilbert Mark John · CIK 0001897698 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2026. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 21:00 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001493152-24-023147 · ownership.xml · derivative · entry 1 Gilbert Mark John · CIK 0001897698 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-06 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on June 6, 2025. Read SEC document |
| May 25, 2023 Filed May 30, 2023 20:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001493152-23-019461 · ownership.xml · derivative · entry 1 Gilbert Mark John · CIK 0001897698 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-05-25 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on May 25, 2024. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 20:30 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 13,750 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001493152-22-027439 · ownership.xml · derivative · entry 1 Gilbert Mark John · CIK 0001897698 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2032-09-30 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on September 30, 2023. Read SEC document |
| December 01, 2021 Filed Dec 9, 2021 02:58 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001493152-21-030884 · ownership.xml · derivative · entry 1 Gilbert Mark John · CIK 0001897698 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-12-01 F1 · derivative.exercise_date: One hundred percent of the stock options vest and become exercisable on December 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.